276 related articles for article (PubMed ID: 7907918)
21. Selective lysis of autologous tumor cells by recurrent gamma delta tumor-infiltrating lymphocytes from renal carcinoma.
Choudhary A; Davodeau F; Moreau A; Peyrat MA; Bonneville M; Jotereau F
J Immunol; 1995 Apr; 154(8):3932-40. PubMed ID: 7706731
[TBL] [Abstract][Full Text] [Related]
22. Defective lymphokine production by most CD8+ and CD4+ tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro.
Guilloux Y; Viret C; Gervois N; Le Dréan E; Pandolfino MC; Diez E; Jotereau F
Eur J Immunol; 1994 Sep; 24(9):1966-73. PubMed ID: 7522155
[TBL] [Abstract][Full Text] [Related]
23. Recombinant interleukin-2-expanded tumor infiltrating lymphocytes from human renal cell cancer do not exhibit autologous tumor cell-specific cytotoxicity.
Nishimura T; Terashima Y; Hattori T; Satoh M; Kondo Y; Kimura G; Yoshida K; Akimoto M
Urol Int; 1991; 47 Suppl 1():83-5. PubMed ID: 1949387
[TBL] [Abstract][Full Text] [Related]
24. Enhanced expression of IFN-gamma mRNA in CD4(+)or CD8(+)tumour-infiltrating lymphocytes compared to peripheral lymphocytes in patients with renal cell cancer.
Elsässer-Beile U; Rindsfüser M; Grussenmeyer T; Schultze-Seemann W; Wetterauer U
Br J Cancer; 2000 Sep; 83(5):637-41. PubMed ID: 10944605
[TBL] [Abstract][Full Text] [Related]
25. T cells expanded from renal cell carcinoma display tumor-specific CD137 expression but lack significant IFN-γ, TNF-α or IL-2 production.
van Asten SD; de Groot R; van Loenen MM; Castenmiller SM; de Jong J; Monkhorst K; Haanen JBAG; Amsen D; Bex A; Spaapen RM; Wolkers MC
Oncoimmunology; 2021 Jan; 10(1):1860482. PubMed ID: 33537169
[TBL] [Abstract][Full Text] [Related]
26. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines.
Schendel DJ; Gansbacher B; Oberneder R; Kriegmair M; Hofstetter A; Riethmüller G; Segurado OG
J Immunol; 1993 Oct; 151(8):4209-20. PubMed ID: 8409397
[TBL] [Abstract][Full Text] [Related]
27. Classification of CD4+ T helper cell clones in human melanoma.
Goedegebuure PS; Lee KY; Matory YL; Peoples GE; Yoshino I; Eberlein TJ
Cell Immunol; 1994 Jun; 156(1):170-9. PubMed ID: 7911074
[TBL] [Abstract][Full Text] [Related]
28. TIL from renal-cell carcinoma: restimulation with tumor influences proliferation and cytolytic activity.
Alexander J; Rayman P; Edinger M; Connelly R; Tubbs R; Bukowski R; Pontes E; Finke J
Int J Cancer; 1990 Jan; 45(1):119-24. PubMed ID: 2298495
[TBL] [Abstract][Full Text] [Related]
29. Modulation of tumor-infiltrating lymphocytes derived from human renal cell carcinoma by interleukin-4.
Tso CL; Duckett T; deKernion JB; Belldegrun AS
J Immunother (1991); 1992 Aug; 12(2):82-9. PubMed ID: 1504057
[TBL] [Abstract][Full Text] [Related]
30. Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer.
Braun MW; Abdelhakim H; Li M; Hyter S; Pessetto Z; Koestler DC; Pathak HB; Dunavin N; Godwin AK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037114
[TBL] [Abstract][Full Text] [Related]
31. Semiquantitative analysis of Th1 and Th2 cytokine expression in CD3+, CD4+, and CD8+ renal-cell-carcinoma-infiltrating lymphocytes.
Elsässer-Beile U; Grussenmeyer T; Gierschner D; Schmoll B; Schultze-Seemann W; Wetterauer U; Schulte Mönting J
Cancer Immunol Immunother; 1999 Jul; 48(4):204-8. PubMed ID: 10431690
[TBL] [Abstract][Full Text] [Related]
32. Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix.
Santin AD; Bellone S; Palmieri M; Bossini B; Roman JJ; Cannon MJ; Bignotti E; Canè S; Pecorelli S
Gynecol Oncol; 2003 May; 89(2):271-80. PubMed ID: 12713991
[TBL] [Abstract][Full Text] [Related]
33. The effects of interleukin-6 on tumor-infiltrating lymphocytes derived from human renal cell cancer.
Lee TY; Koo AS; Peyret C; Shimabukuro T; Dekernion JB; Belldegrun A
J Urol; 1991 Mar; 145(3):663-7. PubMed ID: 1997727
[TBL] [Abstract][Full Text] [Related]
34. In vitro enhanced cytotoxicity of tumor-infiltrating lymphocytes transfected with tumor necrosis factor-related apoptosis-inducing ligand and/or interleukin-2 gene in human renal cell carcinoma.
Tian JQ; Wang ZP; Rodriguez R; Fu JS; Lu JZ; Ma BL
Urology; 2006 May; 67(5):1093-8. PubMed ID: 16635513
[TBL] [Abstract][Full Text] [Related]
35. Lymphokine production by human melanoma tumor-infiltrating lymphocytes.
Salmeron MA; Morita T; Seki H; Platsoucas CD; Itoh K
Cancer Immunol Immunother; 1992; 35(3):211-7. PubMed ID: 1386286
[TBL] [Abstract][Full Text] [Related]
36. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.
Belldegrun A; Muul LM; Rosenberg SA
Cancer Res; 1988 Jan; 48(1):206-14. PubMed ID: 3257161
[TBL] [Abstract][Full Text] [Related]
37. Different expression of Fas and Fas ligand in tumor infiltrating and peripheral lymphocytes of patients with renal cell carcinomas.
Elsässer-Beile U; Gierschner D; Welchner T; Wetterauer U
Anticancer Res; 2003; 23(1A):433-7. PubMed ID: 12680244
[TBL] [Abstract][Full Text] [Related]
38. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
[TBL] [Abstract][Full Text] [Related]
39. MHC class-I-restricted auto-tumor-specific CD4+CD8- T-cell clones established from autologous mixed lymphocyte-tumor-cell culture (MLTC).
Wang P; Vánky F; Klein E
Int J Cancer; 1992 Jul; 51(6):962-7. PubMed ID: 1386348
[TBL] [Abstract][Full Text] [Related]
40. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]